Maxime Dely: What If Whole Blood Became the Standard Again in Massive Transfusion?
Maxime Dely, Therapeutic Solutions Sales Consultant at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“What if whole blood became the standard again in massive transfusion?
In the management of massive hemorrhage, current protocols are well established: alternating red blood cell concentrates, plasma, and platelets – a structured sequence designed to approximate whole blood.
But an important question is increasingly being raised:
Why not use leukoreduced whole blood directly?
The advantages are clear:
- A product that is inherently complete and balanced
- Simplified logistics (single storage condition and unified shelf-life considerations)
- More efficient inventory management
From a scientific standpoint, several recent studies indicate that whole blood offers efficacy comparable to component therapy, particularly regarding early survival and correction of coagulopathy.
Beyond clinical outcomes, this also prompts broader reflection on our organizational models.
And you – have your institutions already begun exploring this shift?”
Find more posts featuring Maxime Dely on Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria